Targeting the immune system to fight cancer using chemical receptor homing vectors carrying polyinosine/cytosine (PolyIC)

Frontiers in Oncology

Volumn 2, Issue FEB, 2012, Pages

  Levitzki, Alexander ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Bystander effect; Cancer; PolyIC

Indexed keywords

ALEMTUZUMAB; BEVACIZUMAB; BRENTUXIMAB VEDOTIN; CD20 ANTIGEN; CD30 ANTIGEN; CD52 ANTIGEN; CETUXIMAB; COMPLEMENT MEMBRANE ATTACK COMPLEX; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPIDERMAL GROWTH FACTOR RECEPTOR; IBRITUMOMAB TIUXETAN; IMMUNOTOXIN; IPILIMUMAB; LAPATINIB; MELANOMA DIFFERENTIATION ASSOCIATED GENE 5 RECEPTOR; PANITUMUMAB; PERTUZUMAB; POLYINOSINE CYTOSINE; POLYNUCLEOTIDE; PROTEIN KINASE R; RECEPTOR; RETINOIC ACID INDUCIBLE PROTEIN I; RINTATOLIMOD; RITUXIMAB; SIPULEUCEL T; STAT3 PROTEIN; TOLL LIKE RECEPTOR 3; TOSITUMOMAB I 131; TRASTUZUMAB; TYRPHOSTIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; APOPTOSIS; BREAST CANCER; BYSTANDER EFFECT; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CHRONIC LYMPHATIC LEUKEMIA; COLON METASTASIS; COMPLEMENT DEPENDENT CYTOTOXICITY; CUTANEOUS T CELL LYMPHOMA; DISEASE ERADICATION; GENE VECTOR; HEAD AND NECK CANCER; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; LARGE CELL LYMPHOMA; LIGAND BINDING; METASTATIC MELANOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RADIOIMMUNOTHERAPY; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL;

EID: 84891646027     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2012.00004     Document Type: Review

References (39)

1. Abourbeh, G., Shir, A., Mishani, E., Ogris, M., Roedl, W., Wagner, E., and Levitzki, A. (2012). PolyIC GE11polyplex inhibits EGFR overexpressing tumors. IUBMB Life (in press).
2. Amann, M., D'Argouges, S., Lorenczewski, G., Brischwein, K., Kischel, R., Lutterbuese, R., Mangold, S., Rau, D., Volkland, J., Pflanz, S., Raum, T., Munz, M., Kufer, P., Schlereth, B., Baeuerle, P. A., and Friedrich, M. (2009). Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release. J. Immunother. 32, 452-464.
3. Benhar, M., Engelberg, D., and Levitzki, A. (2002). ROS, stress-activated kinases and stress signaling in cancer. EMBO Rep. 3, 420-425.
4. Blattman, J. N., and Greenberg, P. D. (2004). Cancer immunotherapy: a treatment for the masses. Science 305, 200-205.
5. Blumberg, B. S. (2010). Primary and secondary prevention of liver cancer by HBV. Front. Biosci. 2, 756-763.
6. Dudley, M. E., Yang, J. C., Sherry, R., Hughes, M. S., Royal, R., Kammula, U., Robbins, P. F., Huang, J., Citrin, D. E., Leitman, S. F., Wunderlich, J., Restifo, N. P., Thomasian, A., Downey, S. G., Smith, F. O., Klapper, J., Morton, K., Laurencot, C., White, D. E., and Rosenberg, S. A. (2008). Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26, 5233-5239.
7. Hanahan, D., and Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674.
8. Hennessy, E. J., Parker, A. E., and O'Neill, L. A. (2010). Targeting Toll-like receptors: emerging therapeutics? Nat. Rev. Drug Discov. 9, 293-307.
9. Hodi, F. S., O'Day, S. J., Mcdermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., Akerley, W., Van Den Eertwegh, A. J., Lutzky, J., Lorigan, P., Vaubel, J. M., Linette, G. P., Hogg, D., Ottensmeier, C. H., Lebbe, C., Peschel, C., Quirt, I., Clark, J. I., Wolchok, J. D., Weber, J. S., Tian, J., Yellin, M. J., Nichol, G. M., Hoos, A., and Urba, W. J. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723.
10. Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., Xu, Y., Frohlich, M. W., and Schellhammer, P. F. (2010). Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411-422.
11. Kenter, G. G., Welters, M. J., Valentijn, A. R., Lowik, M. J., Berends-Van Der Meer, D. M., Vloon, A. P., Essahsah, F., Fathers, L. M., Offringa, R., Drijfhout, J. W., Wafelman, A. R., Oostendorp, J., Fleuren, G. J., Van Der Burg, S. H., and Melief, C. J. (2009). Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med. 361, 1838-1847.
12. Kohler, G., and Milstein, C. (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495-497.
13. Korman, A. J., Peggs, K. S., and Allison, J. P. (2006). Checkpoint blockade in cancer immunotherapy. Adv. Immunol. 90, 297-339.
14. Kortylewski, M., Swiderski, P., Herrmann, A., Wang, L., Kowolik, C., Kujawski, M., Lee, H., Scuto, A., Liu, Y., Yang, C., Deng, J., Soifer, H. S., Raubitschek, A., Forman, S., Rossi, J. J., Pardoll, D. M., Jove, R., and Yu, H. (2009). In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat. Biotechnol. 27, 925-932.
15. Kumar, H., Koyama, S., Ishii, K. J., Kawai, T., and Akira, S. (2008). Cutting edge: cooperation of IPS-1-and TRIF-dependent pathways in poly IC-enhanced antibody production and cytotoxic T cell responses. J. Immunol. 180, 683-687.
16. Lacour, J., Laplanche, A., Delozier, T., Berlie, J., Mourali, N., Julien, J. P., De Gislain, C., Namer, M., Petit, J. C., Denis, V., et al. (1991). Polyadenylic-polyuridylic acid plus locoregional and pelvic radiotherapy versus chemotherapy with CMF as adjuvants in operable breast cancer. A 6 1/2 year follow-up analysis of a randomized trial of the French federation of cancer centers (F.F.C.C.). Breast Cancer Res. Treat. 19, 15-21.
17. Levitzki, A. (1992). Tyrphostins: tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction. FASEB J. 14, 3275-3282.
18. Li, Z., Zhao, R., Wu, X., Sun, Y., Yao, M., Li, J., Xu, Y., and Gu, J. (2005). Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. FASEB J. 19, 1978-1985.
19. Mazzoleni, S., Politi, L. S., Pala, M., Cominelli, M., Franzin, A., Sergi Sergi, L., Falini, A., De Palma, M., Bulfone, A., Poliani, P. L., and Galli, R. (2010). Epidermal growth factor receptor expression identifies functionally and molecularly distinct tumor-initiating cells in human glioblastoma multiforme and is required for gliomagenesis. Cancer Res. 70, 7500-7513.
20. Moschella, F., Proietti, E., Capone, I., and Belardelli, F. (2010). Combination strategies for enhancing the efficacy of immunotherapy in cancer patients. Ann. N. Y. Acad. Sci. 1194, 169-178.
21. Navabi, H., Jasani, B., Reece, A., Clayton, A., Tabi, Z., Donninger, C., Mason, M., and Adams, M. (2009). A clinical grade poly I:C-analogue (Ampligen) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro. Vaccine 27, 107-115.
22. + T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethyl cellulose in patients with recurrent malignant glioma. J. Clin. Oncol. 29, 330-336.
23. Pastan, I., Hassan, R., Fitzgerald, D. J., and Kreitman, R. J. (2006). Immunotoxin therapy of cancer. Nat. Rev. Cancer 6, 559-565.
24. Peggs, K. S., Quezada, S. A., and Allison, J. P. (2008). Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol. Rev. 224, 141-165.
25. Rosenberg, S. A., Restifo, N. P., Yang, J. C., Morgan, R. A., and Dudley, M. E. (2008). Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 8, 299-308.
26. + T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu. Vaccine 24, 5119-5132.
27. Salem, M. L., Kadima, A. N., Cole, D. J., and Gillanders, W. E. (2005). Defining the antigen-specific T-cell response to vaccination and poly(I:C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity. J. Immunother. 28, 220-228.
28. Sampson, J. H., Reardon, D. A., Friedman, A. H., Friedman, H. S., Coleman, R. E., Mclendon, R. E., Pastan, I., and Bigner, D. D. (2005). Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study. Neuro-oncology 7, 90-96.
29. Schafer, A., Pahnke, A., Schaffert, D., Van Weerden, W. M., De Ridder, C. M., Rodl, W., Vetter, A., Spitzweg, C., Kraaij, R., Wagner, E., and Ogris, M. (2011). Disconnecting the Yin and Yang relation of epidermal growth factor receptor (EGFR)-mediated delivery: a fully synthetic, EGFR-targeted gene transfer system avoiding receptor activation. Hum. Gene Ther. 12, 1463-1473.
30. Schaffert, D., Kiss, M., Rodl, W., Shir, A., Levitzki, A., Ogris, M., and Wagner, E. (2011). Poly(I:C)-mediated tumor growth suppression in EGF-receptor overexpressing tumors using EGF-polyethylene glycol-linear polyethylenimine as carrier. Pharm. Res. 28, 731-741.
31. Shir, A., Ogris, M., Roedl, W., Wagner, E., and Levitzki, A. (2011). EGFR-homing dsRNA activates cancer-targeted immune response and eliminates disseminated EGFR-overexpressing tumors in mice. Clin. Cancer Res. 17, 1033-1043.
32. Shir, A., Ogris, M., Wagner, E., and Levitzki, A. (2006). EGF receptor-targeted synthetic double-stranded RNA eliminates glioblastoma, breast cancer, and adenocarcinoma tumors in mice. PLoS Med. 3, e6. doi: 10.1371/journal.pmed.0030006
33. Sistigu, A., Viaud, S., Chaput, N., Bracci, L., Proietti, E., and Zitvogel, L. (2011). Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin. Immunopathol. 33, 369-383.
34. Talmadge, J. E., Adams, J., Phillips, H., Collins, M., Lenz, B., Schneider, M., Schlick, E., Ruffmann, R., Wiltrout, R. H., and Chirigos, M. A. (1985). Immunomodulatory effects in mice of polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose. Cancer Res. 45, 1058-1065.
35. Vesely, M. D., Kershaw, M. H., Schreiber, R. D., and Smyth, M. J. (2011). Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 29, 235-271.
36. Wolf, E., Hofmeister, R., Kufer, P., Schlereth, B., and Baeuerle, P. A. (2005). BiTEs: bispecific antibody constructs with unique anti-tumor activity. Drug Discov. Today 10, 1237-1244.
37. Yoneda, T., Lyall, R. M., Alsina, M. M., Persons, P. E., Spada, A. P., Levitzki, A., Zilberstein, A., and Mundy, G. R. (1991). The antiproliferative effects of tyrosine kinase inhibitors tyrphostins on a human squamous cell carcinoma in vitro and in nude mice. Cancer Res. 51, 4430-4435.
38. Yu, H., Kortylewski, M., and Pardoll, D. (2007). Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 7, 41-51.
39. Yu, H., Pardoll, D., and Jove, R. (2009). STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9, 798-809.